? PROJECT 3 Protective immunity against HIV may be greatly facilitated by the generation of strong immune defenses localized to mucosal portals of entry, where multiple mechanisms of cellular and humoral immunity can participate in virus neutralization. Projects 1 and 2 of this HIVRAD program focus on generating a mechanistic understanding of striking protection observed in macaques through a combination of IgG and IgA antibodies at mucosal surfaces; Project 3 aims to develop immunization methods capable of inducing such immune responses in concert with cellular immunity at mucosal surfaces. We have recently developed a novel strategy to target both polypeptide antigens and molecular adjuvants to lymph nodes, by conjugating these vaccine components to amphiphilic albumin-binding lipid tails, which efficiently causes albumin-mediated lymph node uptake (Liu et al. Nature 2014). This simple modification to create amphiphile (amph)-vaccines increases the T-cell response to molecular vaccines by 30-fold and humoral responses by 20-fold, and greatly increases the therapeutic efficacy of cancer vaccines in mice. This strategy for lymph node targeted adjuvant delivery simultaneously enhances the safety profile of potent molecular adjuvants, by blocking systemic dissemination. It has also recently been demonstrated that mucosal immunization can be dramatically enhanced by exploiting neonatal Fc receptor (FcRn)-mediated transcytosis of Fc-antigen fusion proteins across mucosal barriers. Because albumin is also recycled through FcRn binding, we hypothesize that amph-vaccines will be able to bind to endogenous albumin in interstitial fluid and achieve similar efficient transport across mucosal barriers to permit needle-free mucosal vaccination through the nasal mucosa to promote humoral immunity at distal reproductive tract mucosal sites.
Our specific aims are: (1) Synthesize a set of candidate amphiphile-adjuvants for lymph node targeting of mucosa-draining lymph nodes; (2) Determine limits and best strategies for lymph node targeting of antigens; (3) Define pharmacokinetics and early innate immune/toxicity responses of lymph node-targeted vaccines for mucosal vaccination in non-human primates; and (4) Test the capacity of LN- targeted vaccines to enhance the immunogenicity of HIV subunit vaccines, promote mucosal cellular and humoral immunity, and promote protection against mucosal SHIV challenge in non-human primates. Results from this project will establish the translation of ?albumin hitchhiking? as a strategy to potentiate cellular and humoral to HIV at mucosal surfaces in non-human primates, and test the capacity of this promising new approach to maximize protection against heterologous SHIV challenge through induction of polyfunctional immunity at mucosal portals of entry.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Louisiana at Lafayette
United States
Zip Code
Tokatlian, Talar; Kulp, Daniel W; Mutafyan, Andrew A et al. (2018) Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes. Sci Rep 8:16527
Ruprecht, Ruth M; Lakhashe, Samir K (2017) Antibody-mediated immune exclusion of HIV. Curr Opin HIV AIDS 12:222-228
Ruprecht, Ruth M (2017) Anti-HIV Passive Immunization: New Weapons in the Arsenal. Trends Microbiol 25:954-956
Schneider, Jeffrey R; Carias, Ann M; Bastian, Arangaserry R et al. (2017) Long-term direct visualization of passively transferred fluorophore-conjugated antibodies. J Immunol Methods 450:66-72
Kulkarni, Viraj; Ruprecht, Ruth M (2017) Mucosal IgA Responses: Damaged in Established HIV Infection-Yet, Effective Weapon against HIV Transmission. Front Immunol 8:1581
Sholukh, Anton M; Watkins, Jennifer D; Vyas, Hemant K et al. (2015) Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 33:2086-95
Lakhashe, Samir K; Byrareddy, Siddappa N; Zhou, Mingkui et al. (2014) Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine 32:6527-36
Zhou, Mingkui; Ruprecht, Ruth M (2014) Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109
Sholukh, Anton M; Byrareddy, Siddappa N; Shanmuganathan, Vivekanandan et al. (2014) Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology 11:8
Watkins, Jennifer D; Sholukh, Anton M; Mukhtar, Muhammad M et al. (2013) Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27:F13-20

Showing the most recent 10 out of 77 publications